论文信息 - Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study - 字舞流文

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

I. Bondarenko | C. Ivanescu | V. Mastey | G. Gullo | H. Turk | M. Özgüroğlu | A. Sezer | I. Çiçin | S. Kılıçkap | M. Reaney | Ulrike Naumann | M. Gümüş | P. Rietschel | M. Sasané | G. Konidaris | Siyu Li | Chieh‐I Chen | M. Gogishvili | J. Harnett | Keri J. S. Brady | M. Sasane | Chieh-I. Chen | M. Özgüroğlu